These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

719 related items for PubMed ID: 29852793

  • 1. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.
    Høivik ML, Buer LCT, Cvancarova M, Warren DJ, Bolstad N, Moum BA, Medhus AW.
    Scand J Gastroenterol; 2018 Jun; 53(6):692-699. PubMed ID: 29852793
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study.
    Buer LC, Moum BA, Cvancarova M, Warren DJ, Medhus AW, Høivik ML.
    J Crohns Colitis; 2017 Mar 01; 11(3):297-304. PubMed ID: 27660339
    [Abstract] [Full Text] [Related]

  • 4. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
    Strik AS, van de Vrie W, Bloemsaat-Minekus JPJ, Nurmohamed M, Bossuyt PJJ, Bodelier A, Rispens T, van Megen YJB, D'Haens GR, SECURE study group.
    Lancet Gastroenterol Hepatol; 2018 Jun 01; 3(6):404-412. PubMed ID: 29606564
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience.
    Ratnakumaran R, To N, Gracie DJ, Selinger CP, O'Connor A, Clark T, Carey N, Leigh K, Bourner L, Ford AC, Hamlin PJ.
    Scand J Gastroenterol; 2018 Jun 01; 53(6):700-707. PubMed ID: 29687730
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease.
    Martín-Gutiérrez N, Sánchez-Hernández JG, Rebollo N, Pordomingo AF, Muñoz F, Otero MJ.
    Eur J Hosp Pharm; 2022 Jul 01; 29(4):222-227. PubMed ID: 33115797
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Experience with Biosimilar Infliximab (Remsima®) in Norway.
    Jahnsen J, Kaasen Jørgensen K.
    Dig Dis; 2017 Jul 01; 35(1-2):83-90. PubMed ID: 28147374
    [Abstract] [Full Text] [Related]

  • 12. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results.
    Argüelles-Arias F, Guerra Veloz MF, Perea Amarillo R, Vilches-Arenas A, Castro Laria L, Maldonado Pérez B, Chaaro Benallal D, Benítez Roldán A, Merino V, Ramirez G, Calleja-Hernández MA, Caunedo Álvarez A, Romero Gómez M.
    Eur J Gastroenterol Hepatol; 2017 Nov 01; 29(11):1290-1295. PubMed ID: 28902041
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
    Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, Lundin KEA, Mørk C, Jahnsen J, Kvien TK, NOR-SWITCH study group.
    Lancet; 2017 Jun 10; 389(10086):2304-2316. PubMed ID: 28502609
    [Abstract] [Full Text] [Related]

  • 17. Long-Term Clinical Outcomes After Switching from Remicade® to Biosimilar CT-P13 in Inflammatory Bowel Disease.
    Smits LJT, Grelack A, Derikx LAAP, de Jong DJ, van Esch AAJ, Boshuizen RS, Drenth JPH, Hoentjen F.
    Dig Dis Sci; 2017 Nov 10; 62(11):3117-3122. PubMed ID: 28667429
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease.
    Mahmmod S, Schultheiss JPD, van Bodegraven AA, Dijkstra G, Gilissen LPL, Hoentjen F, Lutgens MWMD, Mahmmod N, van der Meulen-de Jong AE, Smits LJT, Tan ACITL, Oldenburg B, Fidder HH.
    Inflamm Bowel Dis; 2021 Nov 15; 27(12):1954-1962. PubMed ID: 33538298
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.